Cogent Biosciences said its mastocytosis drug helped patients with an advanced form of the blood disease, building on successful data reported over the summer and teeing up a regulatory submission in 2026.
In the Phase …
GSK secured FDA approval for an inflammatory disease drug that it says could reach £3 billion ($4 billion) in peak sales. The agency greenlit depemokimab
Bristol Myers Squibb is the latest large pharma to tap into the speed and efficiency of drug R&D in China. The New York drug giant
DBV Technologies said its peanut allergy patch succeeded in a Phase 3 trial, setting the company up for another FDA submission after a drawn-out saga
FDA Commissioner Marty Makary offered a softer version of the FDA’s view of Covid-19 vaccines than emerged in a recent internal memo, saying that the
Verge Genomics’ sole clinical-stage drug has failed, and the California biotech will shift to a partnership model for its AI-driven discovery platform, Endpoints News has
Cogent Biosciences said its mastocytosis drug helped patients with an advanced form of the blood disease, building on successful data reported over the summer and teeing up a regulatory submission in 2026.
In the Phase …